[HTML][HTML] Parkinson disease-associated cognitive impairment
Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …
Cognitive decline in Parkinson disease
Dementia is a frequent problem encountered in advanced stages of Parkinson disease (PD).
In recent years, research has focused on the pre-dementia stages of cognitive impairment in …
In recent years, research has focused on the pre-dementia stages of cognitive impairment in …
Extracellular vesicle biomarkers for cognitive impairment in Parkinson's disease
Besides motor symptoms, many individuals with Parkinson's disease develop cognitive
impairment perhaps due to coexisting α-synuclein and Alzheimer's disease pathologies and …
impairment perhaps due to coexisting α-synuclein and Alzheimer's disease pathologies and …
Conversion to MCI and dementia in Parkinson's disease: a systematic review and meta-analysis
Objective To systematically review and meta-analyse conversion rates from normal
cognition to Mild Cognitive Impairment (MCI) and dementia in Parkinson's disease (PD) …
cognition to Mild Cognitive Impairment (MCI) and dementia in Parkinson's disease (PD) …
Cognitive decline in Parkinson's disease: the complex picture
Mild cognitive impairment (PD-MCI) and dementia (PDD) are among the most frequent non-
motor symptoms in Parkinson's disease (PD). PD-MCI is six times more likely than age …
motor symptoms in Parkinson's disease (PD). PD-MCI is six times more likely than age …
The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease
BR Bloem, WJ Marks, AL Silva de Lima, ML Kuijf… - BMC neurology, 2019 - Springer
Background Our understanding of the etiology, pathophysiology, phenotypic diversity, and
progression of Parkinson's disease has stagnated. Consequently, patients do not receive …
progression of Parkinson's disease has stagnated. Consequently, patients do not receive …
The role of GPCRs in neurodegenerative diseases: avenues for therapeutic intervention
Y Huang, N Todd, A Thathiah - Current opinion in pharmacology, 2017 - Elsevier
Highlights•GPCRs are implicated in the pathophysiology of various neurodegenerative
diseases.•Currently available therapies do not cure the discussed neurodegenerative …
diseases.•Currently available therapies do not cure the discussed neurodegenerative …
Morphological basis of Parkinson disease-associated cognitive impairment: an update
KA Jellinger - Journal of Neural Transmission, 2022 - Springer
Cognitive impairment is one of the most salient non-motor symptoms of Parkinson disease
(PD) that poses a significant burden on the patients and carers as well as being a risk factor …
(PD) that poses a significant burden on the patients and carers as well as being a risk factor …
Beta amyloid deposition is not associated with cognitive impairment in Parkinson's disease
The extent to which Alzheimer neuropathology, particularly the accumulation of misfolded
beta-amyloid, contributes to cognitive decline and dementia in Parkinson's disease (PD) is …
beta-amyloid, contributes to cognitive decline and dementia in Parkinson's disease (PD) is …
Detecting Mild Cognitive Deficits in P arkinson's D isease: C omparison of N europsychological T ests
J Hoogland, LL van Wanrooij, JA Boel… - Movement …, 2018 - Wiley Online Library
Background: Numerous neuropsychological tests and test versions are used in Parkinson's
disease research, but their relative capacity to detect mild cognitive deficits and their …
disease research, but their relative capacity to detect mild cognitive deficits and their …